Mahamaya Lifesciences
Mahamaya Lifesciences (MAHALIFE) share price was ₹171.00 at the 28 Oct 2026 close; market capitalisation ₹400 Cr; P/E (TTM) 57.00; sector Chemicals. In the Mar 2026 quarter, revenue was ₹166 Cr and net profit was ₹8 Cr. Promoters held 56.39% of Mahamaya Lifesciences in Sep 2026, up 0.04 percentage points from Mar 2026. Its Tapetide Score is 35/100 (Poor) as of 28 Oct 2026.
Key Fundamentals
SMEFertilizers & AgrochemicalsChemicalsPrice-based figures as of 28 Oct 2026, 15:30 IST · TTM
Peer Comparison
Commodities › Chemicals › Pesticides & Agrochemicals
| ₹542.35 | 22.65 | 45,784 Cr | 1.32 | 1.16% | 5.38% | 10.85% | 53,683 Cr | 2,323 Cr | |
| ₹2,107.00 | 27.43 | 31,967 Cr | 2.85 | 0.72% | 11.76% | 14.68% | 6,914 Cr | 1,164 Cr | |
| ₹333.05 | 28.66 | 16,624 Cr | 4.50 | 0.38% | 16.00% | 20.98% | 3,409 Cr | 581 Cr | |
| ₹3,293.90 | 20.22 | 14,803 Cr | 4.99 | 4.59% | 23.24% | 27.93% | 5,761 Cr | 733 Cr | |
| ₹692.95 | 9.98 | 6,252 Cr | 1.99 | 2.31% | 21.71% | 25.26% | 5,464 Cr | 626 Cr | |
| ₹883.75 | 14.84 | 3,940 Cr | 2.34 | 0.23% | 21.17% | 27.37% | 2,071 Cr | 268 Cr | |
| ₹188.10 | 17.08 | 3,658 Cr | 1.67 | 1.58% | 9.68% | 12.75% | 2,631 Cr | 214 Cr | |
| Mahamaya Lifesciences (this company) | — | 57.00 | 400 Cr | 3.28 | 0.00% | 13.55% | 25.18% | 118 Cr | 5 Cr |
| Median 8 companies | ₹692.95 | 21.44 | 10,528 Cr | 2.60 | 0.94% | 14.78% | 23.08% | 4,437 Cr | 604 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 98/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Weaknesses
1- Though the company is reporting repeated profits, it is not paying out dividend
Technical Indicators
Oscillators
Neutral
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year Operating margin 10% · Mar 2026
Quarterly Results
| Particulars | Sep 2024 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 146 | 163 | 166 |
| Expenses | 133 | 148 | 149 |
| Operating Profit | 13 | 15 | 17 |
| OPM % | 9% | 9% | 10% |
| Other Income | 1 | 1 | 1 |
| Interest | 4 | 4 | 4 |
| Depreciation | 1 | 1 | 1 |
| PBT | 10 | 11 | 12 |
| Tax % | 27% | 27% | 35% |
| Net Profit | 7 | 8 | 8 |
| EPS (₹) | 4.08 | 4.71 | 3.48 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 90 | 137 | 161 | 266 | 329 |
| Expenses | 84 | 128 | 148 | 241 | 296 |
| Operating Profit | 6 | 9 | 13 | 25 | 34 |
| OPM % | 7% | 6% | 8% | 9% | 10% |
| Other Income | 0 | 0 | 1 | 1 | 1 |
| Interest | 2 | 3 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 1 | 2 | 2 |
| PBT | 4 | 5 | 7 | 17 | 24 |
| Tax % | 27% | 26% | 27% | 26% | 31% |
| Net Profit | 3 | 4 | 5 | 13 | 17 |
| EPS (₹) | 1.99 | 2.74 | 3.81 | 7.21 | 7.06 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 18 | 23 |
| Reserves | 14 | 18 | 23 | 32 | 99 |
| Borrowings | 19 | 24 | 55 | 58 | 91 |
| Other Liabilities | 21 | 34 | 33 | 81 | 98 |
| Total Liabilities | 56 | 78 | 112 | 188 | 310 |
| Fixed Assets | 20 | 21 | 21 | 27 | 35 |
| CWIP | 2 | 2 | 3 | 4 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 34 | 54 | 88 | 157 | 267 |
| Total Assets | 56 | 78 | 112 | 188 | 310 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 2 | 1 | -23 | 0 | -30 |
| Investing | -3 | -3 | -2 | -7 | -16 |
| Financing | 1 | 2 | 24 | 9 | 81 |
| Net Cash Flow | 0 | 1 | 0 | 1 | 35 |
| Free Cash Flow | -1 | -2 | -25 | -5 | -38 |
| CFO/EBITDA | 56 | 24 | -162 | 6 | -75 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 37 | 25 | 64 | 67 | 78 |
| Inventory Days | 93 | 109 | 137 | 167 | 194 |
| Days Payable | 83 | 87 | 61 | 92 | 88 |
| Cash Conversion Cycle | 47 | 48 | 140 | 142 | 184 |
| Working Capital Days | 8 | 9 | 14 | 29 | 49 |
| ROCE % | — | 20% | 21% | 26% | 20% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Mahamaya Lifesciences insights
53 extracted metrics + investor summaries across FY22–FY26.
Documents
Frequently Asked Questions about Mahamaya Lifesciences
What does Mahamaya Lifesciences Ltd do?
Where is Mahamaya Lifesciences Ltd (MAHALIFE) listed?
Which sector does Mahamaya Lifesciences Ltd belong to?
What is the market capitalisation of Mahamaya Lifesciences Ltd?
What is the PE ratio of Mahamaya Lifesciences Ltd?
What is the 52-week high and low of Mahamaya Lifesciences Ltd?
What is the Return on Equity (ROE) of Mahamaya Lifesciences Ltd?
Company Information
ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544611.md for Mahamaya Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.